• Endovascular procedures at the complex management in patients with portal hypertension and variceal bleeding
en To content Full text of article

Endovascular procedures at the complex management in patients with portal hypertension and variceal bleeding

Paediatric Surgery (Ukraine).2023.3(80):66-70; doi: 10.15574/PS.2023.80.66
Petrushenko V. V., Kedyk O. O.
National Pirogov Memorial Medical University, Vinnytsya, Ukraine

For citation: Petrushenko VV, Kedyk OO. (2023). Endovascular procedures at the complex management in patients with portal hypertension and variceal bleeding. Paediatric Surgery (Ukraine). 3(80): 66-70; doi: 10.15574/PS.2023.80.66.
Article received: Jul 07, 2023. Accepted for publication: Sep 10, 2023.

For today, endovascular procedures, such as embolization of splenic artery, transjugular intrahepatic shunt, and retrograde transvenous obliteration with balloon occlusion are widely applied in the treatment and prophylaxis of variceal bleeding in patients with portal hypertension.
Splenomegaly with the development of hypersplenism is one of complications of portal hypertension in patients with liver cirrhosis, which can negatively be influenced on clinical course. Due to that, it can be assumed that the management of hypersplenism in patients with portal hypertension with the applying of splenic artery embolization, could be improve the results of treatment of this group of patients.
Purpose – to summarize the own experience of the applying of splenic artery embolization in the complex therapy in patients with portal hypertension that complicated by the variceal bleeding.
Materials and methods. This study based on the results of treatment of 36 patients, in which the embolization of splenic artery was applied in the complex management (conventional treatment and endoscopic ligation of varices).
The classic method of “chronic” occlusion was used for the embolization. The embolization on the level of the initial portion of the main trunk of splenic artery was performed in 30 (83.3%) of patients. Due to the anatomical peculiarities of vasculature, embolization was performed on the level of middle part of splenic artery in 6 (16.7%) of patients.
The effectiveness of the treatment was evaluated by the changes of complete blood count indices and ultrasonography results.
Statistical analysis was performed using the program SPSS Statistic for Windows, version 15.0 (IBM Corp., Armonk, NY, USA).
Results. The middle age of patients was 55.8±1.6 years. The middle value of Child-Turcotte-Pugh criterion was 2.44±0.08, and MELD score was 16.36±0.99 value.
Conclusions. The applying of splenic artery embolization that combined with conventional therapy and endoscopic ligation of varices is appropriate and justified. Embolization of the splenic artery promotes to decrease of appearance of hypersplenism in patients with the portal hypertension with positive influence on follow-up clinical course.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution.
The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: portal hypertension, hypersplenism, splenic artery embolization.

REFERENCES

1. Baiges A, Magaz M, Turon F, Hernández-Gea V, García-Pagán JC. (2021). Treatment of acute variceal bleeding in 2021 – when to use transjugular intrahepatic portosystemic shunts? Clinics in Liver Disease. 25 (2): 345-356. https://doi.org/10.1016/j.cld.2021.01.001; PMid:33838854

2. Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ et al. (2021). North american practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clinical Gastroenterology and Hepatology. 20 (8): 1636-1662.e36. https://doi.org/10.1016/j.cgh.2021.07.018; PMid:34274511 PMCid:PMC8760361

3. Chikamori F, Sharma N, Ito S, Mizobuchi K, Ueta K, Takasugi H et al. (2021). Stepwise partial splenic embolization for portal hypertension based on a new concept: Splanchnic caput Medusae. Radiology Case Reports. 16 (3): 564-570. https://doi.org/10.1016/j.radcr.2020.12.020; PMid:33408799 PMCid:PMC7773749

4. Duan X, Zhang K, Han X, Ren J, Xu M, Huang G, Zhang M. (2014). Comparison of percutaneous transhepatic variceal embolization (PTVE) followed by partial splenic embolization versus PTVE alone for the treatment of acute esophagogastric variceal massive hemorrhage. Journal of Vascular and Interventional Radiology. 25 (12): 1858-1865. https://doi.org/10.1016/j.jvir.2014.08.019; PMid:25311969

5. Hadduck TA. (2014). Partial splenic artery embolization in cirrhotic patients. World Journal of Radiology. 6 (5): 160. https://doi.org/10.4329/wjr.v6.i5.160; PMid:24876920 PMCid:PMC4037542

6. Hrubnik VV. (2018). Endovaskuliarni embolizatsii v likuvanni uskladnen portalnoi hipertenzii. Aktualni pytannia suchasnoi khirurhii. Khirurhiia Ukrainy. 4 (68); Dodatok 1: 109-113.

7. Ishikawa T, Sasaki R, Nishimura T, Aibe Y, Saeki I, Iwamoto T et al. (2019). A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification. Plos One. 14 (9): article e0223153. https://doi.org/10.1371/journal.pone.0223153; PMid:31557230 PMCid:PMC6762126

8. Kodama T, Takehara T, Hikita H, Shimizu S, Li W, Miyagi T et al. (2010). Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology. 138 (7): 2487-2498.e7. https://doi.org/10.1053/j.gastro.2010.02.054; PMid:20206174

9. Liu J, Sun X, Ganguli S, Wehrenberg-Klee EP, Bhan I, Zhao Y et al. (2020). Partial splenic embolization is superior to intravenous somatostatin for decreasing portal pressure in cirrhotic patients: A dynamic self-controlled cohort study. Scandinavian Journal of Gastroenterology. 55 (11): 1341-1346. https://doi.org/10.1080/00365521.2020.1831589; PMid:33076704

10. Matsuo R, Ohkohchi N, Murata S, Ikeda O, Nakano Y, Watanabe M et al. (2008). Platelets strongly induce hepatocyte proliferation with IGF-1 and HGF in vitro. Journal of Surgical Research. 145 (2): 279-286. https://doi.org/10.1016/j.jss.2007.02.035; PMid:17688880

11. Ozturk O, Eldem G, Peynircioglu B, Kav T, Görmez A, Cil BE et al. (2016). Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension. World Journal of Gastroenterology. 22 (43): 9623. https://doi.org/10.3748/wjg.v22.i43.9623; PMid:27920483 PMCid:PMC5116606

12. Rachkevych SL, Kushniruk OP. (2014). Multydystsyplinarnyi pidkhid do likuvannia portalnoi hipertenzii, uskladnenoi shlunkovo-kyshkovymy krovotechamy ta hipersplenizmom: suchasna terapiia, endoskopiia, interventsiina radiolohiia. Naukovyi visnyk Uzhhorodskoho universytetu. Seriia: Medytsyna. 1: 137-140.

13. Rosemurgy AS, Molloy DL, Thometz DP, Villadolid DV, Cowgill SM et al. (2007). TIPS in florida: Is its application a result of evidence-based medicine? Journal of the American College of Surgeons. 204 (5): 794-801. https://doi.org/10.1016/j.jamcollsurg.2007.01.014; PMid:17481486

14. Smith M, Ray C. (2012). Splenic artery embolization as an adjunctive procedure for portal hypertension. Seminars in Interventional Radiology. 29 (2): 135-139. https://doi.org/10.1055/s-0032-1312575; PMid:23729984 PMCid:PMC3444868

15. Sun X, Zhang A, Zhou T, Wang M, Chen Y, Zhou T et al. (2021). Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: A multicenter randomized controlled trial. Hepatology International. 15 (3): 741-752. https://doi.org/10.1007/s12072-021-10155-0; PMid:33638769 PMCid:PMC8286949

16. Waguri N, Osaki A, Watanabe Y. (2021). Balloon-occluded retrograde transvenous obliteration for treatment of gastric varices. World Journal of Hepatology. 13 (6): 650-661. https://doi.org/10.4254/wjh.v13.i6.650; PMid:34239700 PMCid:PMC8239489

17. Zhang L, Zhang Z-G, Long X, Liu F-L, Zhang W-G. (2020). Severe complications after splenic artery embolization for portal hypertension due to hepatic cirrhosis. Risk Management and Healthcare Policy. 13: 135-140. https://doi.org/10.2147/RMHP.S234628; PMid:32110126 PMCid:PMC7037048